COVID-19 CD40.RBDv(LinKinVax)(COVID-19 CD40.RBDv(LinKinVax)) - 在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式-

作用机制-

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

Linkinvax SA

在研机构

Linkinvax SA

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 COVID-19 CD40.RBDv(LinKinVax) 相关的临床试验

NCT06255626

/ Recruiting临床1/2期IIT

A Phase 1/2 Multicenter, Randomized Study of the Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
The main questions that will be studied are :
* Is the CD40.RBDv (adjuvanted or not) safe ?
* Does the CD40.RBDv (adjuvanted or not) imply an immunologic response ? Participants will receive, depending on their randomization arm, 1 or 2 injections of the CD40.RBDv vaccine or a single injection of approved mRNA vaccine

开始日期2024-05-27

申办/合作机构